References
- Aller SG, Yu J, Ward A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–22
- Bowalgaha K, Miners J. (2001). The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605–9
- Budde K, Glander P, Diekmann F, et al. (2004). Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5:1333–45
- Bullingham R, Monroe S, Nicholls A, et al. (1996). Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315–24
- Bullingham RES, Nicholls AJ, Kamm BR. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429–55
- De Winter BC, Van Gelder T, Sombogaard F, et al. (2009). Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodynam 36:541–64
- Elbarbry FA, Shoker AS. (2007). Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clin Biochem 40:752–64
- Feng XC, Ding LQ, Qiu F. (2015). Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid. Drug Metab Rev 47:229–38
- Funder JW, Pearce PT, Smith R, et al. (1988). Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583–5
- He P, Wu MC, Li LF, et al. (1998). Effect of glycyrrhizin pretreatment on metabolism of antipyrine and acetaminophen in mice. Chin Pharmaco Bull 14:516–9
- Horikawa M, Kato Y, Tyson CA, et al. (2002). The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17:23–33
- Hou YC, Lin SP, Chao PD. (2012). Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A. Food Chem 135:2307–12
- Hu WY, Li YW, Hou YN, et al. (1999). The induction of liver microsomal cytochrome P450 by Glycyrrhiza uralensis and glycyrrhetinic acid in mice. Biomed Environ Sci 12:10–4
- Ichikawa T, Ishida S, Sakiya Y, et al. (1986). Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J Pharm Sci 75:672–5
- Ishida S, Ichikawa T, Sakiya Y. (1988). Binding of glycyrrhetinic acid to rat plasma, rat serum albumin, human serum, and human serum albumin. Chem Pharm Bull 36:440–3
- Ishida S, Sakiya Y, Ichikawa T, et al. (1989). Binding of glycyrrhizin to human serum and human serum albumin. Chem Pharm Bull 37:226–8
- Ishida S, Sakiya Y, Ichikawa T, et al. (1993). Uptake of glycyrrhizin by isolated rat hepatocytes. Biol Pharm Bull 16:293–7
- Jiao Z, Zhong Y, Shen J, et al. (2005). Simple high-performance liquid chromatographic assay, with post-column derivatization, for simultaneous determination of mycophenolic acd and its gucuronide metabolite in human plasma and urine. Chromatgraphia 62:363–71
- Jiao Z, Zhong JY, Zhang M, et al. (2007). Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 63:27–37
- Li X, Hu J, Wang B, et al. (2014). Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: Herb-drug interactions mediated via P-gp. Toxicol Appl Pharmacol 275:163–75
- Mitchell JR, Jollow DJ, Potter WZ, et al. (1973). Acetaminopheninduced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 187:211–7
- Moon A, Lee MK, Kim SH, et al. (1995). Effect of glycyrrhizae radix on the glucuronidation in rat liver. Arch Pharm Res 18:320–4
- Mu Y, Zhang J, Zhang S, et al. (2006). Traditional Chinese medicines Wu WeiZi (Schisandra chinensis Baill) and GanCao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol ExpTher 316:1369–77
- Naderer OJ, Dupuis RE, Dupuis RE, et al. (2005). The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 45:219–26
- Paolini M, Pozzetti L, Sapone A, et al. (1998). Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 62:571–82
- Picard N, Ratanasavanh D, Premaud A, et al. (2005). Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139–46
- Shargel L, Wu-Pong S, Yu ABC. (2007). Applied biopharmaceutics & pharmacokinetics. New York: McGraw Hill (Sixth edition), 107
- Schutz E, Shipkova M, Armstrong VW, et al. (1999). Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45:419–22
- Shaw LM, Mick R, Nowak I, et al. (1998). Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 38:268–75
- Shaw LM, Pawinski T, Korecka M, et al. (2002). Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit 24:68–73
- Shen B, Li SJ, Zhang Y, et al. (2009). Determination of total, free and saliva mycophenolic acid with a LC–MS/MS method: Application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal 50:515–21
- Shipkova M, Armstrong VW, Wieland E, et al. (1999). Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075–82
- Van Rossum TG, Vulto AG, de Man RA, et al. (1998). Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12:199–205
- Wang Z, Kurosaki Y, Nakayama T, et al. (1994). Mechanism of gastrointestinal absorption of glycyrrhizin in rats. Biol Pharm Bull 17:1399–403
- Westley IS, Brogan LR, Morris RG, et al. (2006). Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261–6
- Westley IS, Morris RG, Evans AM, et al. (2008). Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes. Drug Metab Dispos 36:46–50
- Yan M, Fang PF, Li HD, et al. (2013). Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers. Eur J Clin Pharmacol 69:515–21
- Zhang W, Di LQ, Li JS, et al. (2014). The effects of glycyrrhizae uralenis and its major bioactive components on pharmacokinetics of daphnetin in cortex daphnes in rats. J Ethnopharmacol 154:584–92
- Zucker K, Tsaroucha A, Olson L, et al. (1999). Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35–43